We recently compiled a list of the 10 Hottest Smid-Cap Stocks So Far In 2025. In this article, we are going to take a look at where Senseonics Holdings, Inc. (NYSEAMERICAN:SENS) stands against the other smid-cap stocks.
As the name suggests, smid-cap stocks have a valuation between $200 million and $20 billion. The definition is pretty flexible, but I’ll be working with the broadest one. Most stocks on the market fall into this category, so I think it is a good way to check the general pulse of the broader economy and look into some up-and-coming companies that may one day be the large caps of tomorrow.
We will be taking a look at some of them in this article by looking through stocks within the aforementioned market cap, sorted by their year-to-date gains so far in 2025. Do note that OTC stocks will not be included in this list.
You should keep in mind that while some of these stocks could be good buys, there is also a significant downside risk to stocks that have gained a lot recently.
A patient sitting in their home with the phone app open, tracking their diabetes in real-time.
Senseonics Holdings, Inc. (NYSEAMERICAN:SENS)
YTD Performance: 78.94%
Senseonics Holdings (NYSEAMERICAN:SENS) makes implantable continuous glucose monitoring (CGM) systems that help people with diabetes track their blood sugar in real time. It offers the Eversense line of products. It uses a sensor under the skin that sends data to a transmitter worn on the body, and that transmitter relays readings to a smartphone. This product segment is responsible for most of the company’s revenue because it is the core focus of Senseonics.
Preliminary results show about $22.5 million in total revenue for full-year 2024, and they expect further growth after launching the Eversense 365 system, which received FDA approval. The company also canceled a planned special meeting for a reverse stock split. This has pushed trading interest higher, and many analysts think there is potential for Eversense 365 to gain notice among patients who prefer a long-term CGM solution. Meanwhile, management sees new patient starts on the rise, and they believe the overall user base could expand even more in 2025.
Anyone digging into the nitty-gritty of Senseonics’ finances should know that net losses have remained a factor, but management continues to prioritize product adoption and revenue growth. The company expects positive revenue trends in 2025, and it plans to share updated guidance when the final 2024 results are ready. Investors seem optimistic that the long-term CGM market could give Senseonics a useful niche. The share price has climbed partly because the Eversense 365 system is the first technology of its kind that can last a full year without frequent sensor replacements.
Overall SENS ranks 7th on our list of the hottest smid-cap stocks so far in 2025. While we acknowledge the potential of SENS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SENS but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 10 Hottest Mid-Cap Stocks So Far in 2025 and 10 Hottest Large-Cap Stocks So Far in 2025
Disclosure: None. This article was originally published at Insider Monkey.
Hedge Fund Resource Center